GlassScriptPhysician profile
Shayla Jefferson
NPI 1669926564
$1,818.82
in general payments reported to CMS, 2019-2025
21 companies · $804 in 2025
The $804 reported for 2025 was more than what 76% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $171 · 2024: $843 · 2025: $804.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,819.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,818.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $556.60 | 2023-2025 | Nuedexta, Abilify Maintena, Abilify Asimtufii |
| Abbvie INC. | $377.02 | 2023-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $281.43 | 2024-2025 | Caplyta |
| Lundbeck LLC | $175.33 | 2024-2025 | Abilify Asimtufii, Rexulti |
| Exact Sciences Corporation | $74.53 | 2025 | The Cologuard Plus Collection Kit |
| Pfizer INC. | $50.98 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $45.67 | 2025 | Cobenfy |
| Astellas Pharma US INC | $31.60 | 2025 | Veozah |
| Sage Therapeutics, LLC | $25.19 | 2025 | Zurzuvae |
| Lilly USA, LLC | $20.07 | 2025 | Mounjaro, Zepbound |
| Alnylam Pharmaceuticals INC. | $19.67 | 2024 | Onpattro |
| Takeda Pharmaceuticals U.S.A., INC. | $19.24 | 2024 | Trintellix |
| Aimmune Therapeutics, INC. | $18.56 | 2024 | |
| Phathom Pharmaceuticals, INC. | $16.97 | 2024 | Voquezna |
| Seqirus USA INC | $16.84 | 2025 | Fluad, Flucelvax |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $15.82 | 2024 | Ibsrela |
| Teva Pharmaceuticals USA, INC. | $15.49 | 2025 | Uzedy |
| Bayer Healthcare Pharmaceuticals INC. | $15.39 | 2025 | |
| Novo Nordisk INC | $14.72 | 2024 | Wegovy |
| Viiv Healthcare Company | $14.09 | 2024 | Apretude |
| Novartis Pharmaceuticals Corporation | $13.61 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shayla Jefferson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.